| Rituximab before and during pregnancy A systematic review, and a case series in MS and NMOSD |
30 |
| Expanded autologous regulatory T-lymphocyte infusions in ALS A phase I, first-in-human study |
26 |
| Neuromyelitis optica spectrum disorder Patient experience and quality of life |
23 |
| Multicenter reliability of semiautomatic retinal layer segmentation using OCT |
22 |
| Neurofilament light chain predicts disease activity in relapsing-remitting MS |
22 |
| Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? |
21 |
| Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders |
20 |
| MuSK myasthenia gravis monoclonal antibodies |
20 |
| Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors |
19 |
| Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE) |
18 |
| Pilot study of a ketogenic diet in relapsing-remitting MS |
17 |
| Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS |
16 |
| Cranial nerve involvement in patients with MOG antibody-associated disease |
16 |
| Treatment choices and neuropsychological symptoms of a large cohort of early MS |
14 |
| Cervical spinal cord atrophy An early marker of progressive MS onset |
14 |
| Anti-MOG encephalitis mimicking small vessel CNS vasculitis |
13 |
| Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection |
13 |
| Disease-modifying therapies alter gut microbial composition in MS |
12 |
| Molecular signature of Epstein-Barr virus infection in MS brain lesions |
12 |
| Identification of circulating MOG-specific B cells in patients with MOG antibodies |
12 |
| Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy |
12 |
| Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue |
12 |
| Cladribine tablets added to IFN-beta in active relapsing MS The ONWARD study |
11 |
| Identification of MS-specific serum miRNAs in an international multicenter study |
11 |
| Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD |
10 |
| High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS |
10 |
| Microglial activation, white matter tract damage, and disability in MS |
10 |
| CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection |
10 |
| Monitoring B-cell repopulation after depletion therapy in neurologic patients |
10 |
| Contribution of normal aging to brain atrophy in MS |
10 |
| Immune response to vaccines is maintained in patients treated with dimethyl fumarate |
9 |
| Quantitative spinal cord MRI in radiologically isolated syndrome |
9 |
| Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment |
9 |
| Harmful neutrophil subsets in patients with ischemic stroke Association with disease severity |
8 |
| Natalizumab treatment reduces microglial activation in the white matter of the MS brain |
8 |
| Mouse model of anti-NMDA receptor post-herpes simplex encephalitis |
8 |
| HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLONS disease |
8 |
| IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis |
8 |
| Late-onset neuromyelitis optica spectrum disorder |
8 |
| Real-world validation of the 2017 McDonald criteria for pediatric MS |
8 |
| Varicella-zoster virus CNS vasculitis and RNA polymerase III gene mutation in identical twins |
8 |
| Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI |
8 |
| GABA(A) receptor autoimmunity A multicenter experience |
8 |
| Progressive multifocal leukoencephalopathy A 25-year retrospective cohort study |
8 |
| Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders |
7 |
| GFAP alpha IgG-associated encephalitis upon daclizumab treatment of MS |
7 |
| Pediatric CNS-isolated hemophagocytic lymphohistiocytosis |
7 |
| Gray matter microglial activation in relapsing vs progressive MS A [F-18]PBR06-PET study |
7 |
| Novel clinical features of glycine receptor antibody syndrome A series of 17 cases |
7 |
| Disruption of neurite morphology parallels MS progression |
7 |
